XM does not provide services to residents of the United States of America.
I
I

Incyte


News

U.S. STOCKS Merck, Microstrategy, Illumina

U.S. STOCKS ON THE MOVE-Merck, Microstrategy, Illumina Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the tech-heavy Nasdaq edged higher on Tuesday, paring earlier losses as investors assessed Russia's warning to the United States with a new nuclear doctrine, and awaited quarterly results from AI-heavyweight Nvidia.
G
I
I
I
N
K
U
U
U
J
L

Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte- Sky News Reporter Mark Kleinman On X

BRIEF-Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte- Sky News Reporter Mark Kleinman On X Nov 19 (Reuters) - MERCK IS THE LATEST INDUSTRY GIANT TO BE LINKED TO A TAKEOVER BID FOR INCYTE- SKY NEWS REPORTER MARK KLEINMAN ON X Source https://tinyurl.com/4arax22v
I

U.S. STOCKS Merck, Microstrategy Inc, Zepp Health Corp

BUZZ-U.S. STOCKS ON THE MOVE-Merck, Microstrategy Inc, Zepp Health Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell on Tuesday, as escalating tensions between Russia and Ukraine dented risk appetite globally and sent investors rushing for safe-haven assets.
G
I
I
K
U
U
J
L

Wall Street falls as mounting Russia-Ukraine tensions cause jitters

US STOCKS-Wall Street falls as mounting Russia-Ukraine tensions cause jitters For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Walmart gains after raising annual sales, profit forecast Russell 2000 falls to lowest since Nov. 5 Super Micro surges after auditor appointment Indexes down: Dow 0.78%, S&P 500 0.40%, Nasdaq 0.13% Updates at market open By Lisa Pauline Mattackal and Purvi Agarwal Nov 19 (Reuters) - Wall Street's main indexes fel
A
G
I
J
N
T
U
U
U
U

U.S. STOCKS Piedmont Lithium, Berry, silver miners

BUZZ-U.S. STOCKS ON THE MOVE-Piedmont Lithium, Berry, silver miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures fell as concerns over escalating tensions between Russia and Ukraine affected risk appetite globally, with investors rushing to safe-haven assets.
G
I
K
J
L

Wall Street set to fall as Russia-Ukraine tensions escalate

US STOCKS-Wall Street set to fall as Russia-Ukraine tensions escalate For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Walmart gains after raising annual sales, profit forecast Defense stocks edge higher Super Micro surges after auditor appointment Futures down: Dow 0.67%, S&P 500 0.53%, Nasdaq 0.54% Updates before market open By Lisa Pauline Mattackal and Purvi Agarwal Nov 19 (Reuters) - U.S.
G
I
N
U
U
U
U

Wall St futures dip as Russia-Ukraine tensions escalate

US STOCKS-Wall St futures dip as Russia-Ukraine tensions escalate For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Walmart gains after raising annual sales, profit forecast Super Micro surges after auditor appointment Futures down: Dow 0.53%, S&P 500 0.31%, Nasdaq 0.19% Updates with Walmart results By Lisa Pauline Mattackal and Purvi Agarwal Nov 19 (Reuters) - U.S.
I
N
U
U
U
U

Incyte down after pausing early-stage study on skin condition treatment

BUZZ-Incyte down after pausing early-stage study on skin condition treatment ** Shares of drugmaker Incyte InCY fall about 6% to $72.48 in after-hours trading ** Company to pause enrollment in an on-going early phase study of chronic spontaneous urticaria (CSU) treatment ** Says data from Phase-2 study of its cholestatic pruritus treatment does not
I

US FDA approves Syndax's blood cancer drug

US FDA approves Syndax's blood cancer drug Nov 15 (Reuters) - The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' SNDX.O drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading. The drug revumenib, sold under the brand name Revuforj, is used to treat acute leukemia with a KMT2A translocation, which are chromosomal rearrangements that involve the KMT2A gene and are found in about 10%
I

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BRIEF-Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Nov 7 (Reuters) - Incyte Corp INCY.O : INCYTE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nBw568VWra Further company coverage: INCY.O
I
N

Indian shares post worst session in over a month ahead of US election

INDIA STOCKS-Indian shares post worst session in over a month ahead of US election Updates to close By Bharath Rajeswaran Nov 4 (Reuters) - Indian shares logged their worst session in more than a month on Monday, weighed down by uncertainty around the hotly-contested U .S. presidential election, while volatility spiked to a three-month high. The NSE Nifty 50 .NSEI fell 1 .27 % to 2 3,995.35 , while the BSE Sensex .BSESN lost 1 .18 % to 7 8,782.24 .
I

Indian shares slide on profit booking ahead of US elections, Fed rate decision

INDIA STOCKS-Indian shares slide on profit booking ahead of US elections, Fed rate decision Updates at 11:47 a.m. IST By Bharath Rajeswaran Nov 4 (Reuters) - Indian shares dropped about 2% on Monday, set for their worst session in a month, weighed down by broad-based profit booking, while volatility spiked ahead of the U.S. presidential election and the likelihood of further U.S.
I

Indian shares slide on profit booking ahead of US elections, Fed rate decision

INDIA STOCKS-Indian shares slide on profit booking ahead of US elections, Fed rate decision Updates at 10:14 a.m IST By Bharath Rajeswaran Nov 4 (Reuters) - Indian shares dropped more than 1% on Monday, weighed down by broad-based profit booking, while volatility spiked ahead of the U.S. presidential election and the likelihood of further U.S. interest rate cuts.
I

U.S. Agilon Health, Alphabet, Crocs

U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs Oct 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health, Alphabet and Crocs, on Wednesday. HIGHLIGHTS * Agilon Health Inc AGL.N : Citigroup cuts to sell from neutral * Alphabet Inc GOOGL.O : Seaport Research Partners raises to buy from neutral * Crocs Inc CROX.O : Raymond James cuts to market perform from outperform * Leggett & Platt Inc LEG.N : Piper
A
B
C
G
I
M
Q
V
V
A
E
E
S
U
A
A
F
L
R

Incyte climbs on 2024 sales forecast lift for top-selling drug Jakafi

BUZZ-Incyte climbs on 2024 sales forecast lift for top-selling drug Jakafi ** Shares of drugmaker Incyte INCY.O rise ~8% to $70.95, its highest since May ** Incyte expects 2024 sales of its blood cancer drug Jakafi to be between $2.74 bln and $2.77 bln, compared with its previous forecast of $2.71 bln to $2.75 bln ** Co's Q3 revenue of $1.14 bln, b
I

Incyte Corp reports results for the quarter ended in September 30 - Earnings Summary

Incyte Corp reports results for the quarter ended in September 30 - Earnings Summary Incyte Corp INCY.OQ reported quarterly adjusted earnings of $1.07​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $1.10. The mean expectation of twenty two analysts for the quarter was for earnings of $1.07 per share.
I

Incyte raises 2024 sales forecast for top-selling drug Jakafi

Incyte raises 2024 sales forecast for top-selling drug Jakafi Oct 29 (Reuters) - Incyte INCY.O beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong. Jakafi is approved for use in patients with two types of blood cancers called myelofibrosis and polycythemia vera (PV).
I

Incyte Reports 2024 Third Quarter Financial Results And Provides Updates On Key Clinical Programs

BRIEF-Incyte Reports 2024 Third Quarter Financial Results And Provides Updates On Key Clinical Programs Oct 29 (Reuters) - Incyte Corp INCY.O : INCYTE REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS Source text: ID:nBw4ZpMfCa Further company coverage: INCY.O
I

Incyte Q3 Adjusted EPS USD 1.07 Vs. IBES Estimate USD 1.07

BRIEF-Incyte Q3 Adjusted EPS USD 1.07 Vs. IBES Estimate USD 1.07 Oct 29 (Reuters) - Incyte Q3 EPS USD 0.54. Q3 adjusted operating income USD 255.236 million vs. IBES estimate USD 226.8 million Q3 operating income USD 146.085 million Q3 revenue USD 1,137.871 million vs. IBES estimate USD 1,077 million
I

Election-agitated Treasuries meet megacap earnings

MORNING BID AMERICAS-Election-agitated Treasuries meet megacap earnings A look at the day ahead in U.S. and global markets from Mike Dolan Even as public borrowing estimates were shaved on Monday, U.S. Treasury yields continue to probe three-month highs as markets lean toward a win for Donald Trump in next week's election and a possible clean sweep in Congress for his Republican party.
E
G
G
H
I
M
M
P
P
U
V
A
J
U
U
U
U
E
E
R
S
D
B



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.